Xenetic Biosciences Reports Third Quarter 2026 Financial Results and Highlights Strategic Business Updates
Key Highlights
- ➤Santersus share exchange expected to close Q1 2027, pending Xenetic stockholder approval
- ➤Combined company expected to trade as Santersus Bio under ticker SNTS
- ➤First LBCL patient dosed in Phase I DNase I plus CAR T study
- ➤Third-quarter royalty revenue fell 29% to approximately $0.7 million
- ➤Third-quarter net loss widened to approximately $1.7 million, or $0.72 per share
Expert Statements
James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic Biosciences
“This is a defining period for Xenetic as we work toward completing a transaction that we believe has the potential to fundamentally transform the Company's clinical development profile and long-term value proposition.”
James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic Biosciences
“Santersus is expected to bring an established clinical-stage platform, two FDA Breakthrough Device Designations and a pipeline targeting serious diseases with substantial unmet medical needs.”
James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic Biosciences
“Importantly, the proposed combined company would have multiple development programs and potential catalysts, including an ongoing pivotal sepsis study, planned advancement in lupus and an anticipated oncology clinical readout in 2027.”
James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic Biosciences
“We believe the complementary nature of NucleoCapture® and Xenetic's DNase platform provides a differentiated opportunity to address NETs through distinct mechanisms, potentially expanding the therapeutic reach of the combined platform.”
James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic Biosciences
“Our focus remains on advancing the proposed transaction and positioning the combined organization to execute against its development priorities and build sustainable stockholder value.”
FRAMINGHAM, MA / ACCESS Newswire / November 13, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported financial results for the third quarter ended September 30, 2026, and highlighted its proposed share exchange transaction with Santersus AG ("Santersus"), which is expected to establish a Nasdaq-listed, clinical-stage company with a differentiated pipeline targeting neutrophil extracellular traps (NETs) across multiple high-value therapeutic indications.
"This is a defining period for Xenetic as we work toward completing a transaction that we believe has the potential to fundamentally transform the Company's clinical development profile and long-term value proposition," said James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic Biosciences. "Santersus is expected to bring an established clinical-stage platform, two FDA Breakthrough Device Designations and a pipeline targeting serious diseases with substantial unmet medical needs. Importantly, the proposed combined company would have multiple development programs and potential catalysts, including an ongoing pivotal sepsis study, planned advancement in lupus and an anticipated oncology clinical readout in 2027."
Get started
Create a free account to read the full story.